Review



minzasolmin  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress minzasolmin
    (A) Schematic of experimental design for assessing aging-related symptoms in WT, S129A homozygous (S129A + / + ), and heterozygous (S129A + / − ) mice. (B) Relative change in food-finding latency across genotypes (n=13-25). (C) Relative change in fecal weight across genotypes (n=6-14). (D) Relative change in fecal water content across genotypes (n=6-14). (E) 1-month-old WT and S129A + / + mice injected with AAV-S129D (to restore S129 phosphorylation) or AAV-Vector (control), followed by aging-related behavioral assessments. (F) Food-finding latency in AAV-treated mice (n=6-12). (G) Fecal weight in AAV-treated mice (n=10). (H) Fecal water content in AAV-treated mice (n=10). (I) 1-month-old S129A + / + mice administered <t>Minzasolmin</t> (α-syn aggregation inhibitor) or Captisol (vehicle), followed by aging-related behavioral assessments. (J) Food-finding latency in Minzasolmin/vehicle-treated S129A + / + mice (n=per group sample size). (K) Fecal weight in Minzasolmin/vehicle-treated S129A + / + mice (n=5-7). (L) Fecal water content in Minzasolmin/vehicle-treated S129A + / + mice (n=8). All data are presented as mean ± SEM. Statistical analyses used one-way ANOVA with Tukey’s post hoc test. AAV, adeno-associated virus; KI, knock-in; WT, wild-type.
    Minzasolmin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/minzasolmin/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    minzasolmin - by Bioz Stars, 2026-02
    93/100 stars

    Images

    1) Product Images from "Ser129 Phosphorylation Paradox: Non-phosphorylated α-Synuclein Drives Parkinson’s Disease-like Pathogenesis in Vivo"

    Article Title: Ser129 Phosphorylation Paradox: Non-phosphorylated α-Synuclein Drives Parkinson’s Disease-like Pathogenesis in Vivo

    Journal: bioRxiv

    doi: 10.64898/2025.12.21.695762

    (A) Schematic of experimental design for assessing aging-related symptoms in WT, S129A homozygous (S129A + / + ), and heterozygous (S129A + / − ) mice. (B) Relative change in food-finding latency across genotypes (n=13-25). (C) Relative change in fecal weight across genotypes (n=6-14). (D) Relative change in fecal water content across genotypes (n=6-14). (E) 1-month-old WT and S129A + / + mice injected with AAV-S129D (to restore S129 phosphorylation) or AAV-Vector (control), followed by aging-related behavioral assessments. (F) Food-finding latency in AAV-treated mice (n=6-12). (G) Fecal weight in AAV-treated mice (n=10). (H) Fecal water content in AAV-treated mice (n=10). (I) 1-month-old S129A + / + mice administered Minzasolmin (α-syn aggregation inhibitor) or Captisol (vehicle), followed by aging-related behavioral assessments. (J) Food-finding latency in Minzasolmin/vehicle-treated S129A + / + mice (n=per group sample size). (K) Fecal weight in Minzasolmin/vehicle-treated S129A + / + mice (n=5-7). (L) Fecal water content in Minzasolmin/vehicle-treated S129A + / + mice (n=8). All data are presented as mean ± SEM. Statistical analyses used one-way ANOVA with Tukey’s post hoc test. AAV, adeno-associated virus; KI, knock-in; WT, wild-type.
    Figure Legend Snippet: (A) Schematic of experimental design for assessing aging-related symptoms in WT, S129A homozygous (S129A + / + ), and heterozygous (S129A + / − ) mice. (B) Relative change in food-finding latency across genotypes (n=13-25). (C) Relative change in fecal weight across genotypes (n=6-14). (D) Relative change in fecal water content across genotypes (n=6-14). (E) 1-month-old WT and S129A + / + mice injected with AAV-S129D (to restore S129 phosphorylation) or AAV-Vector (control), followed by aging-related behavioral assessments. (F) Food-finding latency in AAV-treated mice (n=6-12). (G) Fecal weight in AAV-treated mice (n=10). (H) Fecal water content in AAV-treated mice (n=10). (I) 1-month-old S129A + / + mice administered Minzasolmin (α-syn aggregation inhibitor) or Captisol (vehicle), followed by aging-related behavioral assessments. (J) Food-finding latency in Minzasolmin/vehicle-treated S129A + / + mice (n=per group sample size). (K) Fecal weight in Minzasolmin/vehicle-treated S129A + / + mice (n=5-7). (L) Fecal water content in Minzasolmin/vehicle-treated S129A + / + mice (n=8). All data are presented as mean ± SEM. Statistical analyses used one-way ANOVA with Tukey’s post hoc test. AAV, adeno-associated virus; KI, knock-in; WT, wild-type.

    Techniques Used: Injection, Phospho-proteomics, Plasmid Preparation, Control, Virus, Knock-In



    Similar Products

    minzasolmin  (MedChemExpress)
    93
    MedChemExpress minzasolmin
    (A) Schematic of experimental design for assessing aging-related symptoms in WT, S129A homozygous (S129A + / + ), and heterozygous (S129A + / − ) mice. (B) Relative change in food-finding latency across genotypes (n=13-25). (C) Relative change in fecal weight across genotypes (n=6-14). (D) Relative change in fecal water content across genotypes (n=6-14). (E) 1-month-old WT and S129A + / + mice injected with AAV-S129D (to restore S129 phosphorylation) or AAV-Vector (control), followed by aging-related behavioral assessments. (F) Food-finding latency in AAV-treated mice (n=6-12). (G) Fecal weight in AAV-treated mice (n=10). (H) Fecal water content in AAV-treated mice (n=10). (I) 1-month-old S129A + / + mice administered <t>Minzasolmin</t> (α-syn aggregation inhibitor) or Captisol (vehicle), followed by aging-related behavioral assessments. (J) Food-finding latency in Minzasolmin/vehicle-treated S129A + / + mice (n=per group sample size). (K) Fecal weight in Minzasolmin/vehicle-treated S129A + / + mice (n=5-7). (L) Fecal water content in Minzasolmin/vehicle-treated S129A + / + mice (n=8). All data are presented as mean ± SEM. Statistical analyses used one-way ANOVA with Tukey’s post hoc test. AAV, adeno-associated virus; KI, knock-in; WT, wild-type.
    Minzasolmin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/minzasolmin/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    minzasolmin - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Schematic of experimental design for assessing aging-related symptoms in WT, S129A homozygous (S129A + / + ), and heterozygous (S129A + / − ) mice. (B) Relative change in food-finding latency across genotypes (n=13-25). (C) Relative change in fecal weight across genotypes (n=6-14). (D) Relative change in fecal water content across genotypes (n=6-14). (E) 1-month-old WT and S129A + / + mice injected with AAV-S129D (to restore S129 phosphorylation) or AAV-Vector (control), followed by aging-related behavioral assessments. (F) Food-finding latency in AAV-treated mice (n=6-12). (G) Fecal weight in AAV-treated mice (n=10). (H) Fecal water content in AAV-treated mice (n=10). (I) 1-month-old S129A + / + mice administered Minzasolmin (α-syn aggregation inhibitor) or Captisol (vehicle), followed by aging-related behavioral assessments. (J) Food-finding latency in Minzasolmin/vehicle-treated S129A + / + mice (n=per group sample size). (K) Fecal weight in Minzasolmin/vehicle-treated S129A + / + mice (n=5-7). (L) Fecal water content in Minzasolmin/vehicle-treated S129A + / + mice (n=8). All data are presented as mean ± SEM. Statistical analyses used one-way ANOVA with Tukey’s post hoc test. AAV, adeno-associated virus; KI, knock-in; WT, wild-type.

    Journal: bioRxiv

    Article Title: Ser129 Phosphorylation Paradox: Non-phosphorylated α-Synuclein Drives Parkinson’s Disease-like Pathogenesis in Vivo

    doi: 10.64898/2025.12.21.695762

    Figure Lengend Snippet: (A) Schematic of experimental design for assessing aging-related symptoms in WT, S129A homozygous (S129A + / + ), and heterozygous (S129A + / − ) mice. (B) Relative change in food-finding latency across genotypes (n=13-25). (C) Relative change in fecal weight across genotypes (n=6-14). (D) Relative change in fecal water content across genotypes (n=6-14). (E) 1-month-old WT and S129A + / + mice injected with AAV-S129D (to restore S129 phosphorylation) or AAV-Vector (control), followed by aging-related behavioral assessments. (F) Food-finding latency in AAV-treated mice (n=6-12). (G) Fecal weight in AAV-treated mice (n=10). (H) Fecal water content in AAV-treated mice (n=10). (I) 1-month-old S129A + / + mice administered Minzasolmin (α-syn aggregation inhibitor) or Captisol (vehicle), followed by aging-related behavioral assessments. (J) Food-finding latency in Minzasolmin/vehicle-treated S129A + / + mice (n=per group sample size). (K) Fecal weight in Minzasolmin/vehicle-treated S129A + / + mice (n=5-7). (L) Fecal water content in Minzasolmin/vehicle-treated S129A + / + mice (n=8). All data are presented as mean ± SEM. Statistical analyses used one-way ANOVA with Tukey’s post hoc test. AAV, adeno-associated virus; KI, knock-in; WT, wild-type.

    Article Snippet: Minzasolmin (UCB0599, MedChemExpress, NJ, USA) was dissolved in a vehicle solution containing 40% Captisol (Aladdin, Shanghai, China) in sterile water.

    Techniques: Injection, Phospho-proteomics, Plasmid Preparation, Control, Virus, Knock-In